skip to Global Navigation Bar skip to main content

homeHome > R&D > Pipeline


Daewoong Pharmaceutical’s R&D Division

wil focus its skills and resources on chronic and intractable diseases that are in high demand from the market and such areas of interest as improvement of the quality of life and provide patients with innovative drugs (chemical or bio), incrementally modified drugs, and new botanical treatments.

New Chemical Entity

New Chemical Entity table
Project MOA Description Status(KR)
R Pre P1 P2 P3 M
DWP14012 APA (Reversible) GERD, Peptic ulcer
DWP305401† Pellino-1 inhibitor Ulcerative Colitis
DWP16001 SGLT2 inhibitor Diabetes
DWN12088 PRS inhibitor Fibrotic disease (IPF)
DWP17061 Nav1.7 blocker Inflammatory pain, Neuropathic pain, Cancer pain
DWP212525 JAK3/BTK inhibitor Autoimmune disease
(Pemphigus Vulgaris, RA, SLE)
DWP213388 ITK/BTK inhibitor Autoimmune disease

†Collaboration with Bridge Biotherapeutics

Biologics & Regenerative Medicine

Biologics & Regenerative Medicine table
Project MOA Description Status(KR)
R Pre P1 P2 P3 M
Nabota* Botulinum Toxin Glabellar lines (US/EU) US
Novosis Bone regen. (BMP-2) Biomedical device for spinal fusion
(Injectable type, TLIF)
HL036† Anti-TNF alpha Dry eye syndrome (US)
Regenerative Medicine hES-MSC Stroke
Dementia/Alzheimer's disease
Idiopathic Pulmonary Fibrosis
DWP457 Long-acting Insulin Type 1 and 2 Diabetes
DWP458 Undisclosed Osteoporosis
HL186†, HL187† Undisclosed Immuno-oncology

Collaboration with *Evolus and †HanAll Biopharma